Current Edition

2nd

AstraZeneca won’t submit lung drug for COPD after 2nd study miss

AstraZeneca no longer plans to seek approval of its new respiratory biologic Fasenra in chronic obstructive pulmonary disease (COPD) after the second of two Phase 3 …

Continue Reading →